Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-3329
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series ; volume:6 ; number:1 ; day:1 ; month:11 ; year:2016 ; pages:1-6 ; date:12.2016
Clinical Sarcoma Research ; 6, Heft 1 (1.11.2016), 1-6, 12.2016
- Urheber
-
Lipplaa, Astrid
- Beteiligte Personen und Organisationen
-
Dijkstra, Sander
Gelderblom, Hans
SpringerLink (Online service)
- DOI
-
10.1186/s13569-016-0059-x
- URN
-
urn:nbn:de:1111-2016112420307
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lipplaa, Astrid
- Dijkstra, Sander
- Gelderblom, Hans
- SpringerLink (Online service)
Ähnliche Objekte (12)
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Phototoxic Reaction Induced by Pazopanib
Pazopanib and Statin-Induced Rhabdomyolysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Identification of functional dependencies in chordoma
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Phototoxic Reaction Induced by Pazopanib
Pazopanib and Statin-Induced Rhabdomyolysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
Identification of functional dependencies in chordoma
Einfluss der Tyrosinkinase-Inhibitoren Sorafenib, Sunitinib und Pazopanib auf die zelluläre Aktivität von Nierenkarzinom-Zellen
Pharmacometric approaches for linking pharmacokinetic and pharmacodynamic models of sunitinib and pazopanib with clinical outcome
Reversible Hypopigmentation with Pazopanib
Sunitinib-Sorafenib- versus Sunitinib-Everolimus-Sequenztherapie beim Nierenzellkarzinom
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
Phototoxic Reaction Induced by Pazopanib
Pazopanib and Statin-Induced Rhabdomyolysis
Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis